Market Exclusive

Analyst Activity – Chardan Capital Lowers Its Price Target On Spring Bank Pharmaceuticals (NASDAQ:SBPH) to $30.00

Analyst Ratings For Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Today, Chardan Capital lowered its price target on Spring Bank Pharmaceuticals (NASDAQ:SBPH) to $30.00 per share.

There are 1 hold rating, 4 buy ratings on the stock.

The current consensus rating on Spring Bank Pharmaceuticals (NASDAQ:SBPH) is Buy (Score: 2.80) with a consensus target price of $26.25 per share, a potential 94.88% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Spring Bank Pharmaceuticals (NASDAQ:SBPH)
Spring Bank Pharmaceuticals (NASDAQ:SBPH) has insider ownership of 17.60% and institutional ownership of 9.82%.

Recent Trading Activity for Spring Bank Pharmaceuticals (NASDAQ:SBPH)
Shares of Spring Bank Pharmaceuticals closed the previous trading session at 13.47 down -0.12 -0.88% with 26,594 shares trading hands.

Exit mobile version